Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2025-11-19 00:00:00 ET · period of report 2025-11-18 · accession 0001683168-25-008537 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | 2025-11-18 | PHIO | Bitterman Robert J | COB, Pres, CEO, Dir | P - Purchase | $1.27 | +5,000 | 276.4K | +2% | +$6,350 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.0001 par value | 2025-11-18 | P | A | 5,000 | $1.27 | 276,421 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. |